Jacobs Levy Equity Management
AMPH icon

Jacobs Levy Equity Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Jacobs Levy Equity Management’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-28,616
Closed -$1.14M – 950
2024
Q2 		$1.14M Sell
28,616
-166,369
-85% -$6.89M ﹤0.01% 702
2024
Q1 		$8.56M Sell
194,985
-13,530
-6% -$699K 0.04% 325
2023
Q4 		$12.9M Sell
208,515
-346,335
-62% -$18.2M 0.07% 270
2023
Q3 		$25.5M Buy
554,850
+171,642
+45% +$9.36M 0.15% 154
2023
Q2 		$22M Buy
383,208
+256,827
+203% +$11.4M 0.13% 185
2023
Q1 		$4.74M Sell
126,381
-64,291
-34% -$2.11M 0.03% 412
2022
Q4 		$5.34M Buy
190,672
+2,633
+1% +$76.5K 0.04% 380
2022
Q3 		$5.28M Buy
188,039
+910
+0.5% +$29.7K 0.04% 383
2022
Q2 		$6.51M Buy
187,129
+74,613
+66% +$2.66M 0.05% 366
2022
Q1 		$4.04M Sell
112,516
-74,813
-40% -$2.12M 0.03% 469
2021
Q4 		$4.36M Sell
187,329
-13,799
-7% -$282K 0.03% 457
2021
Q3 		$3.82M Buy
201,128
+11,051
+6% +$216K 0.03% 488
2021
Q2 		$3.83M Buy
190,077
+65,847
+53% +$1.24M 0.03% 487
2021
Q1 		$2.28M Sell
124,230
-9,886
-7% -$184K 0.02% 572
2020
Q4 		$2.7M Sell
134,116
-28,811
-18% -$561K 0.02% 513
2020
Q3 		$3.06M Sell
162,927
-10,645
-6% -$214K 0.03% 439
2020
Q2 		$3.9M Buy
173,572
+2,306
+1% +$42.2K 0.04% 392
2020
Q1 		$2.54M Sell
171,266
-8,339
-5% -$145K 0.03% 429
2019
Q4 		$3.46M Buy
179,605
+2,284
+1% +$43.8K 0.03% 440
2019
Q3 		$3.52M Buy
177,321
+109,189
+160% +$2.27M 0.04% 398
2019
Q2 		$1.44M Sell
68,132
-4,821
-7% -$101K 0.02% 578
2019
Q1 		$1.49M Buy
72,953
+37,628
+107% +$843K 0.02% 572
2018
Q4 		$703K Hold
35,325
– – 0.01% 674
2018
Q3 		$680K Buy
+35,325
New +$630K 0.01% 717

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jacobs Levy Equity Management's AMPH Position: Q3 2024 in Review

Jacobs Levy Equity Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2024, closing a stake of 28,616 shares — an estimated $1.14M sold.

Jacobs Levy Equity Management first reported a position in AMPH in Q3 2018 and held it in 24 quarters. The position peaked at $25.5M in Q3 2023. 279 funds tracked by Wall St. Rank hold AMPH as of Q3 2024.

  • Jacobs Levy Equity Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 28,616 Amphastar Pharmaceuticals shares in Q3 2024, an estimated $1.14M.
  • Jacobs Levy Equity Management first reported a position in Amphastar Pharmaceuticals in Q3 2018 and held it in 24 quarters.
  • Jacobs Levy Equity Management's Amphastar Pharmaceuticals position peaked at $25.5M in Q3 2023.
  • 279 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q3 2024, filed 14 Nov 2024.